These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25745736)

  • 1. Stem cell collection considerations for AL amyloidosis.
    Gehrie EA; Booth GS
    Conn Med; 2014; 78(10):587-90. PubMed ID: 25745736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term survival after autologous peripheral blood stem cell transplantation in a patient with primary AL amyloidosis complicating congestive heart failure].
    Saito M; Hayashi T; Nojima M; Ikeda H; Tarasawa I; Yasui H; Ishida T; Adachi M; Imai K; Shinomura Y
    Rinsho Ketsueki; 2007 Nov; 48(11):1478-83. PubMed ID: 18080505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Autologous peripheral blood hematopoietic cell transplantation in the treatment of AL-amyloidosis].
    Smirnova AG; Smirnov AV; Zander A; Afanas'ev BV
    Ter Arkh; 2010; 82(10):61-4. PubMed ID: 21341467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal perforation early after peripheral blood stem cell transplantation for AL amyloidosis.
    Schulenburg A; Kalhs P; Oberhuber G; Reiter E; Base W; Greinix HT
    Bone Marrow Transplant; 1998 Aug; 22(3):293-5. PubMed ID: 9720746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of nephrotic syndrome due to systemic AL amyloidosis after autologous stem cell transplantation: renal response is an important therapeutic end point.
    Akay OM; Sahin G; Kabukcuoglu S; Yalcin AU; Gulbas Z
    Clin Nephrol; 2008 Apr; 69(4):294-7. PubMed ID: 18397705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
    Herrmann SM; Gertz MA; Stegall MD; Dispenzieri A; Cosio FC; Kumar S; Lacy MQ; Dean PG; Prieto M; Zeldenrust SR; Buadi FK; Russell SJ; Nyberg SL; Hayman SR; Dingli D; Fervenza FC; Leung N
    Nephrol Dial Transplant; 2011 Jun; 26(6):2032-6. PubMed ID: 21543655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
    Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
    Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
    Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
    Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
    [TBL] [Abstract][Full Text] [Related]  

  • 11.  Liver transplantation followed by autologous stem cell transplantation for acute liver failure caused by AL amyloidosis. Case report and review of the literature.
    Elnegouly M; Specht K; Zoller H; Matevossian E; Bassermann F; Umgelter A
    Ann Hepatol; 2016; 15(4):592-7. PubMed ID: 27236160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical analysis of autologous stem cell transplantation for nine cases of cardiac amyloidosis].
    Ogura M; Sekine R; Nishiyama S; Abe Y; Iizuka H; Kusaka S; Nakagawa Y; Suzuki K
    Rinsho Ketsueki; 2012 Jul; 53(7):710-5. PubMed ID: 22975774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
    Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
    Oran B; Malek K; Sanchorawala V; Wright DG; Quillen K; Finn KT; La Valley M; Skinner M; Seldin DC
    Bone Marrow Transplant; 2005 Mar; 35(6):567-75. PubMed ID: 15665842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL cardiac amyloidosis.
    Yagi S; Akaike M; Ozaki S; Moriya C; Takeuchi K; Hara T; Fujimura M; Sumitomo Y; Iwase T; Ikeda Y; Aihara K; Kimura T; Nishiuchi T; Abe M; Matsumoto T
    Intern Med; 2007; 46(20):1705-10. PubMed ID: 17938525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
    Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
    J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea.
    Kim SJ; Lee GY; Jang HR; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
    Amyloid; 2013 Dec; 20(4):204-11. PubMed ID: 23914780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
    Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
    Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.